ATE526035T1 - Tollwut-impfstoff - Google Patents

Tollwut-impfstoff

Info

Publication number
ATE526035T1
ATE526035T1 AT04023168T AT04023168T ATE526035T1 AT E526035 T1 ATE526035 T1 AT E526035T1 AT 04023168 T AT04023168 T AT 04023168T AT 04023168 T AT04023168 T AT 04023168T AT E526035 T1 ATE526035 T1 AT E526035T1
Authority
AT
Austria
Prior art keywords
vaccine
rabs
dose
reduced
rabies vaccine
Prior art date
Application number
AT04023168T
Other languages
English (en)
Inventor
Angelika Banzhoff
Claudius Malerczyk
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE526035T1 publication Critical patent/ATE526035T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04023168T 2004-05-07 2004-09-29 Tollwut-impfstoff ATE526035T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56917204P 2004-05-07 2004-05-07

Publications (1)

Publication Number Publication Date
ATE526035T1 true ATE526035T1 (de) 2011-10-15

Family

ID=35079556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04023168T ATE526035T1 (de) 2004-05-07 2004-09-29 Tollwut-impfstoff

Country Status (2)

Country Link
EP (1) EP1593392B1 (de)
AT (1) ATE526035T1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1928562B (zh) * 2006-09-22 2011-05-18 中国科学院微生物研究所 一种检测狂犬病病毒的酶联免疫试剂盒
AU2013229465A1 (en) 2012-03-07 2014-09-04 Novartis Ag Adjuvanted formulations of rabies virus immunogens
CN106163554B (zh) 2014-12-23 2021-09-07 依生生物制药(新加坡)私人有限公司 一种包含pika佐剂的狂犬病组合物
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096462A1 (en) * 2001-02-15 2004-05-20 Rangarajan Pundi Narasimhan Noval vaccine formulation consisting of dna vaccine and inactivated virus

Also Published As

Publication number Publication date
EP1593392B1 (de) 2011-09-28
EP1593392A1 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
DE60142615D1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
PT1415002E (pt) Tecnologia focada em anticorpos
CY1112851T1 (el) Μεθοδος προληψης ή θεραπειας μολυνσης μ. τuβεrculosis
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
ATE499112T1 (de) Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
EA200702633A1 (ru) Вакцина против малярии
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
NO20023935D0 (no) Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
ATE286745T1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
ATE407209T1 (de) Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen
ATE526035T1 (de) Tollwut-impfstoff
DE60333370D1 (de) Zur bildung von partikeln fähiges hbv-precore-protein
ATE471990T1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
EA200700017A1 (ru) Способ усиления иммунного ответа на вакцину
TNSN08184A1 (en) Chimeric antigens and vaccines
ATE495758T1 (de) Virulentes systemisches felines calicivirus
DE60327544D1 (de) Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
WO2002074332A3 (en) Method to enhance the immunogenicity of an antigen
RU2001106408A (ru) Способ стимуляции образования антител при иммунизации лабораторных животных
RU2004130267A (ru) Способ вакцинации детей против краснухи на крайнем севере

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties